Evotec’s Autobahn Labs Accelerating Drug Development at UCLA and now UCSF

Evotec’s Autobahn Labs Accelerating Drug Development at UCLA and now UCSF

Autobahn labs, a virtual incubator partnered with top academic and research centers to catalyze early-stage drug discovery and development, recently inked a strategic collaboration deal with the preeminent University of California San Francisco (UCSF). The two organizations will collaborate to identify promising early science with significant therapeutic potential, forming joint owned ventures to accelerate the translation of scientific ideas to novel therapeutics. Autobahn Labs represents an innovative approach to accelerate research from idea to commercialization. By bringing together a leading German-based drug discovery and development firm (Evotec) and well-capitalized life science investors, tight partnerships with major academic medical centers could shake up the drug development industry as known today. The goal of these sophisticated partnerships: get to the most promising ideas first; mobilize sophisticated discovery and development capabilities and infrastructure; drive clinical development; and accelerate drugs to commercialization. The winners in this race stand to not only help humanity but also generate huge returns along the way.

TrialSite provides a brief ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee